Page header

Recommendation of the President – Lyvdelzi (seladelpar)

On 28 April 2026, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 60/2026 on the inclusion of the medicinal product Lyvdelzi (seladelpar) in the reimbursement program under the new drug program “Treatment of patients with primary biliary cholangitis (PBC) (ICD-10: K74.3)”

Publication in Public Information Bulletin (BIP) >>